Company Filing History:
Years Active: 2020-2023
Title: Kevin Drew: Innovator in Oxopiperazine Research
Introduction
Kevin Drew is a notable inventor based in Austin, TX (US). He has made significant contributions to the field of pharmaceutical research, particularly in the development of oxopiperazine compounds. With a total of 3 patents, his work focuses on innovative solutions for gene expression control and cancer treatment.
Latest Patents
One of Kevin Drew's latest patents is titled "Oxopiperazine helix mimetics for control of hypoxia-inducible gene expression." This invention relates to oxopiperazines that mimic helix αB of the C-terminal transactivation domain of HIF1α. The patent also discloses pharmaceutical compositions containing these oxopiperazines and methods for their use, including reducing gene transcription and treating disorders mediated by the interaction of HIF1α with CREB-binding protein and/or p300. Another significant patent is "Oxopiperazine helix mimetics as inhibitors of the p53-MDM2 interaction." This invention involves oligooxopiperazines that modulate the p53-Mdm2 interaction, providing potential therapeutic avenues for cancer treatment.
Career Highlights
Kevin Drew is affiliated with New York University, where he continues to advance his research in pharmaceutical sciences. His work has garnered attention for its potential impact on treating various medical conditions, particularly those related to gene expression and cancer.
Collaborations
Some of his notable coworkers include Paramjit S Arora and Brooke Bullock Lao, who contribute to the collaborative research environment at New York University.
Conclusion
Kevin Drew's innovative work in oxopiperazine research highlights his commitment to advancing medical science. His patents reflect a dedication to finding new solutions for complex health issues.